n°175

October 2016

Issue Contents
Editorial

Free  Advances too rarely implemented

p.228
Why is it so difficult to put proven advances into practice?

Marketing Authorisations

Ruxolitinib (Jakavi°) and polycythaemia vera

p.229-231
Inconclusive evaluation

INN Common stem: -pride

p.231

Ibrutinib (Imbruvica°) and Waldenström's macroglobulinaemia

p.232
Uncertain efficacy but real dangers

Bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer

p.233
Prolongs survival by a few months, but highly toxic

Free  Prucalopride and chronic constipation in men (Resolor°)

p.234
Avoid in both men and women

Intravenous cangrelor (Kengrexal°) and coronary angioplasty

p.235-236
No advantage over first-line clopidogrel

Dulaglutide (Trulicity°) weekly in type 2 diabetes

p.236-237
Cardiovascular reactions should be better documented

Adverse Effects

Metoclopramide, domperidone: sudden cardiac death, ventricular arrhythmia

p.238-240

Domperidone: long trivialised, this is a drug to avoid

p.239

Nicorandil: so much needless suffering

p.241

Anastrozole: carpal tunnel syndrome

p.242

Adrenaline autoinjectors: lacerations

p.242

Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation

p.242

Canagliflozin: increased risk of toe amputations?

p.243

Idelalisib: deaths from infections

p.243

Quinine, cramps and heart failure: deaths

p.243

Reviews

Actinic keratosis

p.244-245
First-choice treatments

Ezetimibe + statin: insufficient benefit

p.245-246
No reduction in mortality

Exercise useful for elderly women

p.246
Reduction in injurious falls

Outlook

MedDRA and pharmacovigilance

p.247-250
A complex and little-evaluated tool

Doping in East Germany: drugs as a geopolitical tool

p.251
The lessons of history

Masthead

Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe